Spectrum Healthcare Partners turns to Proscia for cancer diagnosis

Proscia, a leading provider of digital and computational pathology solutions, has announced that Spectrum Healthcare Partners (SHCP), an independent, multispecialty, physician-owned healthcare practice, has selected Concentriq Dx to modernise its pathology operations.

In adopting Proscia’s software platform, SHCP will increase access to high-quality diagnostic services across Maine and New Hampshire, better informing treatment decisions for more patients. As SHCP serves patients across various healthcare systems, it recognised an opportunity to pioneer the use of digital pathology in its region to expand the reach of its subspecialist experts and deliver timely results.

“We believe that all patients, regardless of geography, deserve access to high-quality care,” said Bilal R Ahmad MD MBA FCAP Managing Director, Pathology Division at Spectrum Healthcare Partners. “Concentriq Dx is critical to decentralising our diagnostic services. It will enable us to seamlessly transition to digital pathology at scale so that we can reimagine our day-to-day operations beyond the confines of our physical laboratory spaces.”

Concentriq Dx is a modern digital pathology platform that drives diagnostic workflows for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, it provides faster, broader access to subspecialist experts, helping more patients to begin the best treatment sooner. The platform also offers world-class interoperability with leading scanners and image analysis applications and is designed for realising the promise of pathology’s AI-powered future to meet evolving needs.

“We are excited to welcome Spectrum Healthcare Partners to the growing roster of hospital systems and diagnostic laboratories adopting Concentriq Dx,” said David West, Proscia’s CEO. “Our organizations share a strong commitment to the patient, and we are thrilled that SHCP sees the value of modern digital pathology in democratizing diagnosis and helping to improve treatment decisions.”


Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024